NUTM2B antisense RNA 1 (NUTM2B-AS1)

NUTM2B-AS1 is a long non-coding RNA gene located in a region prone to trinucleotide (CCG) repeat expansion[1][3]. Such expansions in NUTM2B-AS1 are linked to rare, inherited neuromuscular disorders, notably oculopharyngeal myopathy with leukoencephalopathy type 1 (OPML1) and a variant of oculopharyngodistal myopathy (OPDM5)[1][3]. Typically, control subjects have 3–16 CCG repeats at this locus, while disease alleles can have hundreds (up to ~700)[3]. NUTM2B-AS1 is transcribed in close proximity and bidirectionally with another non-coding gene, LOC642361. Current research suggests the mechanism involves toxic effects of repeat expansions, likely mediated by aberrant RNA foci or translation of toxic proteins via repeat-associated non-ATG (RAN) translation[1]. NUTM2B-AS1 is not considered a therapeutic target such as an enzyme or receptor, but its repeat expansion serves as a biomarker for specific forms of myopathies[1][3]. No drugs are known to specifically interact with this molecule, and there is no established mechanism of action for pharmacological targeting. The pathological mechanism is believed to involve RNA toxicity, phase separation, and possibly aberrant protein production through RAN translation, analogously to other repeat expansion diseases[1][2]. No specific safety or therapeutic challenges are documented, as it is not yet a drug target. There are also no reported use cases for patient selection or efficacy monitoring beyond genetic diagnosis for repeat expansions.

Other names

OPML1NUTM2B-AS1